WHAT IF A COMPANY USED THE SAME SCIENTIFIC BREAKTHROUGHS REVOLUTIONIZING ONCOLOGY TO FIGHT INFECTIOUS DISEASE?
Vir was created to be that company.
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Lead investors include ARCH Venture Partners and the Bill & Melinda Gates Foundation, and will be joined by others including sovereign wealth funds, public mutual funds and prominent individuals and family offices.
Vir Biotechnology is investing in cures, treatments, and preventions for challenging viral and bacterial diseases, including those caused by drug-resistant bacteria and emerging pathogens.
The Vir team is comprised of world leaders in immunology, infectious disease, and drug development. We work together to discover new cures for infectious diseases impacting populations around the world. Learn more about our executive team, board of directors, and scientific advisors below.
SAN FRANCISCO—Vir Biotechnology, Inc. today announced it is launching to develop cures, treatments, and preventions for challenging infectious diseases, with former Biogen CEO George Scangos heading a team of scientific and industry leaders. The company will be headquartered in the San Francisco, California, area and...READ MORE